Background- Therapies beyond hypomethylating agents such as azacitidine are needed in high-risk myelodysplastic syndromes. Venetoclax is an orally bioavailable small molecule BCL-2 inhibitor that is synergistic with hypomethylating agents. We therefore aimed to evaluate the safety, tolerability, and preliminary activity...

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Valera Duration: 40mins https://www.nature.com/articles/s41591-022-02017-5

Βρείτε συνημμένη την παρουσίαση του Καθ. Αλέξανδρου Σπυριδωνίδη με θέμα "Chimeric Antigen Receptor-T cells (CART cells)" που πραγματοποιήθηκε στις 24 Σεπτεμβρίου 2022 στην επιστημονική συνάντηση με τίτλο «Βελτιστοποιώντας το παρόν, ανοίγοντας νέους ορίζοντες»  

Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm Prof. Naveen Pemmaraju, Prof. Alexandros Spyridonidis https://youtu.be/fYF55Yb97gI

This article was authored and presented by Prof. Spyridonidis. Participants: Dr. Liga, Dr. Tsokanas, Dr. Valera  Duration: 40mins In this registry-based study which includes acute myeloid leukemia patients who underwent a matched unrelated donor allogeneic peripheral-blood stem cell transplantation in complete remission and...

Participants: Dr Liga, Dr Tsokanas, Dr Valera, Zoi Panagi (Pharmassist) Presenter: Prof. Spyridonidis Duration: 40 mins Therapeutic options for patients with AML relapsing after allogeneic HCT range from chemotherapy or hypomethylating agents with or without donor lymphocyte infusions to a 2nd allogeneic HCT. Available...

https://mds-risk-model.com/ by The International Working Group for the Prognosis of MDS  -  Bernard et al. NEJM Evidence 2022

Schematic guidelines for CRS and iTTP management were presented and discussed Presenter: Prof Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Valera, Zoi Panagi (Pharmassist)

Germ-line missense mutations in PTPN11, the gene coding SHP-2, have been discovered as a major molecular event underlying Noonan syndrome, an autosomal dominant trait characterized by short stature, dysmorphic facies, and congenital heart defects, as well as in other closely related developmental disorders....

THE EBMT acitivity in the COVIDera has ebnn published and discussed Presenter A Spyridonidis Part: ML, DT, CL, ES, NC

Novel approaches for the treatment of ALL in adults were discussed. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Valera Duration: 30 mins

We discussed about copper deficiency in myelodysplastic syndrome (MDS) patients Presenter: Prof Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Valera Duration: 40 mins

The combination of venetoclax and gilteritinib is a highly active and tolerable oral combination regimen that potentially improves response frequency and depth over existing standards in a high-risk, mutation-defined group of patients with AML. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr...

We discussed about preliminary analysis of the prospective, multicenter, phase III NEUTRODIET trial, which is studying the effects of diet on infection rates during neutropenia in patients undergoing autologous (auto)- or allogeneic (allo)‑HSCT. Data presented at EHA2022 Presenter: Prof. Spyridonidis Participants: Dr. Liga,...

The new molecular m-IPSS is presented Presenter Prof. Spyridonidis Participants Dr. Liga, Dr Tsokanas, Dr. Valera  Duration: 30 mins 

Integrating Morphological, Clinical, and Genomic Data 2022 ELN International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data 5th WHO Presenter: Prof. Spyridonidis Participants: Dr. Liga, Dr Tsokanas, Dr. Valera  Duration: 30 mins 

Efficacy and safety of 10-day DEC followed by allografting to IC followed by allografting in older fit AML patients was discussed. Presenter: Prof. Spyridonidis Participants: Dr. Tsokanas, Dr. Liga, Dr. Valera Duration: 30 mins